BOLT
Bolt Biotherapeutics, Inc. - Common Stock (BOLT)
$54
About Bolt Biotherapeutics, Inc. - Common Stock (BOLT)
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Details
Daily high
$6.54
Daily low
$6.16
Price at open
--
52 Week High
$7.78
52 Week Low
$3.10
Market cap
12.7M
Dividend yield
-
Volume
10
Avg. volume
716,929
P/E ratio
-.40
Bolt Biotherapeutics, Inc. - Common Stock News
Details
Daily high
$6.54
Daily low
$6.16
Price at open
--
52 Week High
$7.78
52 Week Low
$3.10
Market cap
12.7M
Dividend yield
-
Volume
10
Avg. volume
716,929
P/E ratio
-.40